Skip to content
10-K

Annual Report

PROVECTUS BIOPHARMACEUTICALS, INC. PVCT

0001493152-26-012726

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 23, 2026 420.28M sh
Shares Diluted FY 2025 · Dec 31, 2025 420.28M sh
Shares Diluted FY 2025 · Dec 31, 2024 419.81M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$3.33M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$3.28M
Cash And Equivalents FY 2025 · Dec 31, 2025 $251.29K
Cash And Equivalents FY 2025 · Dec 31, 2024 $307.44K
Stockholders Equity FY 2025 · Dec 31, 2025 −$6.3M
Stockholders Equity FY 2025 · Dec 31, 2024 −$5.96M
Current Liabilities FY 2025 · Dec 31, 2025 $6.9M
Current Liabilities FY 2025 · Dec 31, 2024 $6.98M
Total Liabilities FY 2025 · Dec 31, 2025 $7M
Total Liabilities FY 2025 · Dec 31, 2024 $6.98M
Current Assets FY 2025 · Dec 31, 2025 $567.87K
Current Assets FY 2025 · Dec 31, 2024 $976.77K
Total Assets FY 2025 · Dec 31, 2025 $697.5K
Total Assets FY 2025 · Dec 31, 2024 $1.01M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.01
Eps Diluted FY 2025 · Dec 31, 2024 −$0.01
Eps Basic FY 2025 · Dec 31, 2025 −$0.01
Eps Basic FY 2025 · Dec 31, 2024 −$0.01
Sga Expense FY 2025 · Dec 31, 2025 $3.73M
Sga Expense restated FY 2025 · Dec 31, 2024 $3.1M
Rd Expense FY 2025 · Dec 31, 2025 $1.9M
Rd Expense restated FY 2025 · Dec 31, 2024 $2.05M
Net Income FY 2025 · Dec 31, 2025 −$5.43M
Net Income FY 2025 · Dec 31, 2024 −$4.73M
Operating Income FY 2025 · Dec 31, 2025 −$5.29M
Operating Income FY 2025 · Dec 31, 2024 −$4.53M
Revenue FY 2025 · Dec 31, 2025 $336.11K
Revenue FY 2025 · Dec 31, 2024 $617.14K